SpeedWeed

AUGUST 16, 2021

During the keynote session titled “Sue’n the DEA: The Story of a Cannabis Research Breakthrough,” Dr. Sisley—a pioneering medical cannabis researcher and volunteer medical director for more than 40 state cannabis licenses—will share her journey on navigating scientific and legal complexities of medical cannabis research.

Media 52

Media Clinical Trials DEA Hemp 52

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. A few months later, the agency awarded BTD for Usona Institute ‘s psilocybin therapy for major depressive disorder. Then, something strange happened.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

MedicalJane

JUNE 29, 2018

“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.” The Next Move Is On The DEA. Epidiolex’s launch is in the hands of the DEA. ” –FDA Commissioner Scott Gottlieb.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” Alternative therapies to opioid treatment like medical cannabis will help the VA’s effort to deal with the opioid epidemic.

Law 62

Law Chronic Pain Conditions Legislation 62

Canna Care Docs

SEPTEMBER 26, 2019

An open-minded approach toward alternative therapies Possess an active Connecticut medical license issued by the Connecticut Department of Public Health. Possess an active controlled substance registration issued by the Connecticut Department of Consumer Protection that is not subject to limitation. Why Work for CannaCareDocs?

History 40

History DEA Therapy Patients 40

Cannabis Law Report

JULY 27, 2021

UC Davis consistently ranks as one of the top plant sciences programs in the world and shares our commitment to applying a deeper scientific rigor to cannabis research in order to further our understanding behind the potentially life-saving applications of cannabinoid medicine. About Biopharmaceutical Research Company.

Research and Development 98

Research and Development Pharmaceutical Sativa Extraction 98

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. CBD Scheduling Rule Change. But the government is clear.

CBD 99

CBD DEA Research and Development Hemp 99

Veriheal

JUNE 29, 2021

In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. The FDA refers to this program as the expanded access program on their website. Cannabinoid Therapies for Cancer Patients.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Cybin (NYSE: CYBN).

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

CannaMD

SEPTEMBER 10, 2020

Is it safe to continue cannabis-based therapies during pregnancy? This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented.

Marijuana 59

Marijuana Therapy Data THC 59

MedicalJane

JUNE 29, 2018

There is no universal handbook for a medical cannabis program. The best way to become familiar with your state’s medical marijuana program is to visit its official website. Doctors may not prescribe cannabis products to patients because marijuana is currently listed as an example of a Schedule I drug according to the DEA.

Patients 83

Patients Legalization Conditions Treatment 83

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. In contrast, it is unclear to what extent people most in need of psychedelic therapies will benefit.

Law 105

Law Research and Development Therapy DEA 105

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare. “Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. NEWS PROVIDED BY.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 12, 2022

Virginia 2024 adult use program may be postponed: [link]. Investor discusses need for therapy with psychedelics: [link]. DEA grants research license for psychedelics and major depression first human trial: [link]. Missouri to vote on adult use: [link]. Colorado opens consumption hotel: [link].

DEA 98

DEA Dispensary Hemp Therapy 98

The Cannigma

MAY 15, 2023

While costs to access ketamine therapy can be high in some locations, and like any drug ketamine is not a cure-all, some patients and their doctors have been reporting life-changing results when no other treatment provided relief. 1 Related Stories What’s the deal with ketamine?

Therapy 78

Therapy Access Blood Pressure Treatment 78

The Cannigma

FEBRUARY 16, 2022

So, we are partnering with the Harrington Institute to provide two different cohorts here in Chicago, program we have going on. One cohort is specializing in essentially a reentry program. And proficiency testing right now, because of the DEA is very limited in what can get sent out.

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73

SMPL

FEBRUARY 11, 2020

President Trump proposed ending an existing policy that protects state medical marijuana programs from Justice Department interference as part of his fiscal year 2021 budget plan released on Monday. through the High Intensity Drug Trafficking Area program, the document states. through regulations and guidance.”.

Research and Development 40

Research and Development Legalization Marijuana Programs 40

Cannabis Info

MARCH 26, 2019

It typically does NOT send users into addiction rehab programs. Plans were in the works to implement such programs; Department of Agriculture. I feel that if it was taken off the list and proved to the DEA, FDA, or whoever else…that it isn’t a narcotic then we can get some headway on this wonderful, helpful plant.

Marijuana 51

Marijuana Hemp Blood Pressure Oil 51

Cannabis Law Report

JULY 30, 2019

The informed patients, cannabis industry employees, and clinicians find it equally difficult to keep updated on Florida’s latest medical marijuana program news and changes. . Cannabis is not a “gateway” drug, according to the ASA and the DEA’s own statements cited in the August 2016 U.S. Federal Register. .

Marijuana 45

Marijuana Patients Research and Development Programs 45

Veriheal

MAY 13, 2022

According to the Drug Enforcement Administration (DEA) website , magic mushrooms are recognizable by their slender stems, which are “topped by caps with dark gills on the underside.” Once consumed—whether fresh or dried in the form of a brewed tea or an edible—this hallucinogenic chemical transforms into psilocin.

Research and Development 98

Research and Development Legalization Consumption Microdosing 98

Cannabis Law Report

JUNE 27, 2022

The Drug Enforcement Administration (DEA) said in a letter that marijuana seed that has a delta-9-THC concentration of not more than 0.3% million in the first month following launch of the program. [link]. OR Heath Authority accepting applications from psilocybin training programs: [link]. ” shorturl.at/fyXZ3.

Seed-To-Sale 52

Seed-To-Sale Hemp Retail Treatment 52